Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Cancer Institute is offering funding to support research projects under the Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) program, which aims to enhance understanding of the biological effects of radiation from radionuclides used in radiopharmaceutical therapy. This initiative encourages multidisciplinary research combining cancer biology, radiation biology, radiochemistry, imaging, dosimetry, and preclinical modeling to investigate how different types of radionuclide radiation impact normal tissues, tumor cells, and the tumor microenvironment. The goal is to generate foundational biological insights that will inform the development of new targeting strategies, optimized treatment regimens, and combination therapies to improve the precision and effectiveness of cancer treatments involving radiopharmaceuticals. The funding opportunity consolidates previous exploratory and research funding mechanisms into a streamlined application process, maintaining support for ongoing research momentum in this domain. Applicants can propose exploratory or developmental projects lasting up to two years or more extensive research projects lasting four to five years. Overall, the STRIPE program seeks to expand the scientific knowledge base related to radiopharmaceutical therapy, facilitate entry for investigators in cancer biology, and accelerate the production of reproducible, mechanistically driven data. These efforts aim to enable more personalized and effective use of radiopharmaceutical therapies in oncology.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support research projects that employ state-of-the-art cancer biology approaches and preclinical model systems to investigate the biological effects of radiation emitted by radionuclides used in radiopharmaceutical therapy (RPT). The focus of this initiative is to advance mechanistic understanding of how different forms of radionuclide-emitted radiation affect normal tissues, tumor cells, and the tumor microenvironment, and how these effects can be leveraged to improve therapeutic outcomes. This NOFO will support the Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) program. The overarching goal of STRIPE is to stimulate multidisciplinary research that integrates cancer biology, radiation biology, radiochemistry, imaging, dosimetry, and preclinical modeling. Funded projects are expected to generate fundamental biological insights that can serve as the foundation for the development of new targeting strategies, optimized treatment regimens, and innovative combination approaches for RPT, ultimately leading to more effective and precise anticancer therapies.
This NOFO consolidates prior exploratory/developmental and research project funding mechanisms to streamline the application process and sustain momentum in this critical research area. The applicants have the option of submitting either for exploratory/developmental research projects with a project period of up to 2 years or for research projects with a project period of 4 to 5 years. Collectively, the STRIPE program is intended to broaden the scientific base of RPT research, lower barriers to entry for cancer biology investigators, and accelerate the generation of reproducible, mechanistically informed data that will enable more effective and personalized use of radiopharmaceutical therapies in cancer care.
